Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension
The Journal of Clinical Hypertension · 2023
DOI: 10.1111/jch.14656 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2023. Verfasst von Ki-Chul Sung und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Republic of Ko…. Hauptthemen laut MEDLINE: Hypertension, Hypotension. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We compared the efficacy and safety of third‐standard‐dose triple and third‐standard‐dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double‐blind, parallel‐group trial. After a 4‐week placebo run‐in period, 245 participants were randomized to the third‐dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third‐dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was ‐18.3 ± 13.2, ‐13.0 ± 13.3, ‐16.3 ± 12.4, and ‐13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 ( P = .010 and P = .018, respectively) and 8 ( P = .017 and P = .036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups ( P = .013, P = .021, and P = .045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups ( P = .022 and P = .049, respectively) at week 8. Third‐standard‐dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third‐standard‐dose dual combination therapies, without increasing adverse drug reactions in patients with mild‐to‐moderate hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Republic of Korea.
- Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
- Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang-si, Gyeonggi, Republic of Korea.
- Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
- Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Cardiology Division, Cardiac center, CHA Bundang medical center, CHA University, Seongnam, Republic of Korea.
ORCID-Profile: Ki-Chul Sung, Moo-Yong Rhee, Myung-Ho Jeong, Hae-Young Lee, Sungha Park, Jinho Shin, Wook-Bum Pyun
Zitieren
APA
Sung, K. C., Hong, S. J., Rhee, M. Y., Jeong, M. H., Kim, D. H., Lim, S. W., Park, K., Lee, J. B., Kim, S. Y., Cho, J. M., Cho, G. Y., Heo, J. H., Kim, S. H., Lee, H. Y., Kim, W., Cho, D. K., Park, S., Shin, J., Pyun, W. B., …, & Jung, J. A. (2023). Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14656
Vancouver
Sung KC, Hong SJ, Rhee MY, Jeong MH, Kim DH, Lim SW, et al. Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension. The Journal of Clinical Hypertension. 2023. doi:10.1111/jch.14656
BibTeX
@article{Sung2023,
author = {Sung, Ki-Chul and Hong, Soon Jun and Rhee, Moo-Yong and Jeong, Myung-Ho and Kim, Dae-Hee and Lim, Sang-Wook and Park, Kyungil and Lee, Jin Bae and Kim, Seok-Yeon and Cho, Jin-Man and Cho, Goo-Yeong and Heo, Jung-Ho and Kim, Sang-Hyun and Lee, Hae-Young and Kim, Weon and Cho, Deok-Kyu and Park, Sungha and Shin, Jinho and Pyun, Wook-Bum and Kwon, Kihwan and Rha, Seung-Woon and Jung, Jin-A},
title = {Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension},
journal = {The Journal of Clinical Hypertension},
year = {2023},
doi = {10.1111/jch.14656}
}
EUVIMED